ZVRA Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. (ZVRA) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is $0.14 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.1% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Zevra Therapeutics, Inc.
Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options.
Sector
Healthcare
Industry
Drug Manufacturers/Other